I
260.71
1.33 (0.51%)
| Previous Close | 259.38 |
| Open | 258.75 |
| Volume | 465,391 |
| Avg. Volume (3M) | 795,118 |
| Market Cap | 18,308,644,864 |
| Price / Earnings (TTM) | 45.03 |
| Price / Earnings (Forward) | 62.50 |
| Price / Sales | 9.30 |
| Price / Book | 15.11 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 |
| Profit Margin | 20.19% |
| Operating Margin (TTM) | 16.03% |
| Diluted EPS (TTM) | 5.79 |
| Quarterly Revenue Growth (YOY) | 17.20% |
| Quarterly Earnings Growth (YOY) | -2.50% |
| Total Debt/Equity (MRQ) | 118.37% |
| Current Ratio (MRQ) | 3.58 |
| Operating Cash Flow (TTM) | 430.30 M |
| Levered Free Cash Flow (TTM) | 155.28 M |
| Return on Assets (TTM) | 6.80% |
| Return on Equity (TTM) | 43.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | Insulet Corporation | Mixed | Bullish |
AIStockmoo Score
0.6
| Analyst Consensus | 2.0 |
| Insider Activity | -2.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 0.0 |
| Average | 0.60 |
|
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.38% |
| % Held by Institutions | 102.93% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 355.00 (Citigroup, 36.17%) | Buy |
| Median | 324.00 (24.28%) | |
| Low | 266.00 (Barclays, 2.03%) | Hold |
| Average | 321.20 (23.20%) | |
| Total | 8 Buy, 2 Hold | |
| Avg. Price @ Call | 221.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wolfe Research | 13 May 2025 | 350.00 (34.25%) | Buy | 0.000 |
| Oppenheimer | 09 May 2025 | 324.00 (24.28%) | Buy | 0.000 |
| Barclays | 30 Apr 2025 | 266.00 (2.03%) | Hold | 260.71 |
| RBC Capital | 06 Mar 2025 | 340.00 (30.41%) | Buy | 259.67 |
| Canaccord Genuity | 21 Feb 2025 | 324.00 (24.28%) | Buy | 282.80 |
| Citigroup | 21 Feb 2025 | 355.00 (36.17%) | Buy | 282.80 |
| Piper Sandler | 21 Feb 2025 | 310.00 (18.91%) | Buy | 282.80 |
| Raymond James | 21 Feb 2025 | 328.00 (25.81%) | Buy | 282.80 |
| Stifel | 21 Feb 2025 | 293.00 (12.39%) | Hold | 282.80 |
| Wells Fargo | 21 Feb 2025 | 322.00 (23.51%) | Buy | 282.80 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHADWICK ANA MARIA | - | 260.71 | -1,765 | -460,153 |
| Aggregate Net Quantity | -1,765 | |||
| Aggregate Net Value ($) | -460,153 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 260.71 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CHADWICK ANA MARIA | Officer | 01 May 2025 | Disposed (-) | 1,765 | 260.71 | 460,153 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |